Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.64 USD | +1.89% | -8.27% | -23.86% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.86% | 10.26B | |
+36.04% | 3.04B | |
-8.23% | 2.94B | |
-12.92% | 2.19B | |
-15.92% | 1.72B | |
+63.82% | 1.4B | |
+31.25% | 780M | |
-4.59% | 736M | |
-16.12% | 560M | |
-0.60% | 293M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023